These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 17501690)

  • 1. Aripiprazole acts as a selective dopamine D2 receptor partial agonist.
    Wood M; Reavill C
    Expert Opin Investig Drugs; 2007 Jun; 16(6):771-5. PubMed ID: 17501690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
    Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F
    Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.
    Burris KD; Molski TF; Xu C; Ryan E; Tottori K; Kikuchi T; Yocca FD; Molinoff PB
    J Pharmacol Exp Ther; 2002 Jul; 302(1):381-9. PubMed ID: 12065741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.
    Keck PE; McElroy SL
    Expert Opin Investig Drugs; 2003 Apr; 12(4):655-62. PubMed ID: 12665420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
    Stark AD; Jordan S; Allers KA; Bertekap RL; Chen R; Mistry Kannan T; Molski TF; Yocca FD; Sharp T; Kikuchi T; Burris KD
    Psychopharmacology (Berl); 2007 Feb; 190(3):373-82. PubMed ID: 17242925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms.
    Egashira N; Okuno R; Matsushita M; Abe M; Mishima K; Iwasaki K; Nishimura R; Oishi R; Fujiwara M
    Eur J Pharmacol; 2008 Sep; 592(1-3):103-8. PubMed ID: 18644366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
    Mamo D; Graff A; Mizrahi R; Shammi CM; Romeyer F; Kapur S
    Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.
    Shapiro DA; Renock S; Arrington E; Chiodo LA; Liu LX; Sibley DR; Roth BL; Mailman R
    Neuropsychopharmacology; 2003 Aug; 28(8):1400-11. PubMed ID: 12784105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats.
    Marona-Lewicka D; Nichols DE
    Psychopharmacology (Berl); 2004 Apr; 172(4):415-21. PubMed ID: 14647959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of brexpiprazole: comparison with aripiprazole.
    Stahl SM
    CNS Spectr; 2016 Feb; 21(1):1-6. PubMed ID: 26899451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.
    Jordan S; Koprivica V; Chen R; Tottori K; Kikuchi T; Altar CA
    Eur J Pharmacol; 2002 Apr; 441(3):137-40. PubMed ID: 12063084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
    Keks N; Hope J; Schwartz D; McLennan H; Copolov D; Meadows G
    CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.
    Aihara K; Shimada J; Miwa T; Tottori K; Burris KD; Yocca FD; Horie M; Kikuchi T
    Brain Res; 2004 Apr; 1003(1-2):9-17. PubMed ID: 15019558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
    Gründer G; Kungel M; Ebrecht M; Göröcs T; Modell S
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S21-5. PubMed ID: 16508892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
    Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
    Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist.
    Hirose T; Kikuchi T
    J Med Invest; 2005 Nov; 52 Suppl():284-90. PubMed ID: 16366516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization.
    Koener B; Goursaud S; Van De Stadt M; Calas AG; Jeanjean AP; Maloteaux JM; Hermans E
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Jan; 383(1):65-77. PubMed ID: 21061116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
    Tadori Y; Forbes RA; McQuade RD; Kikuchi T
    Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission.
    Tanahashi S; Yamamura S; Nakagawa M; Motomura E; Okada M
    Neuropharmacology; 2012 Feb; 62(2):765-74. PubMed ID: 21925189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.